APMD market overview

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Latest price: $22.49
Daily change: +0.00%
Market state: closed
As of: 2026-09-23 19:30:01 ET

The interactive chart loads with current market data when StockStorm starts.

Market information is provided for research and visualization and is not investment advice.